Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Estimation of Stratified Mark-Specific Proportional Hazards Models under Two-Phase Sampling with Application to HIV Vaccine Efficacy Trials.

Yang G, Sun Y, Qi L, Gilbert PB.

Stat Biosci. 2017 Jun;9(1):259-283. doi: 10.1007/s12561-016-9177-5. Epub 2016 Oct 27.

PMID:
28781713
2.

Opportunities and Challenges for Environmental Exposure Assessment in Population-Based Studies.

Patel CJ, Kerr J, Thomas DC, Mukherjee B, Ritz B, Chatterjee N, Jankowska M, Madan J, Karagas MR, McAllister KA, Mechanic LE, Fallin MD, Ladd-Acosta C, Blair IA, Teitelbaum SL, Amos CI.

Cancer Epidemiol Biomarkers Prev. 2017 Sep;26(9):1370-1380. doi: 10.1158/1055-9965.EPI-17-0459. Epub 2017 Jul 14. Review.

PMID:
28710076
3.

Variable selection for case-cohort studies with failure time outcome.

Ni AI, Cai J, Zeng D.

Biometrika. 2016 Sep;103(3):547-562. doi: 10.1093/biomet/asw027. Epub 2016 Aug 10.

4.

Body mass index, PAM50 subtype, recurrence, and survival among patients with nonmetastatic breast cancer.

Cespedes Feliciano EM, Kwan ML, Kushi LH, Chen WY, Weltzien EK, Castillo AL, Sweeney C, Bernard PS, Caan BJ.

Cancer. 2017 Jul 1;123(13):2535-2542. doi: 10.1002/cncr.30637. Epub 2017 Mar 13.

PMID:
28295245
5.

Improving efficiency of parameter estimation in case-cohort studies with multivariate failure time data.

Yan Y, Zhou H, Cai J.

Biometrics. 2017 Jan 23. doi: 10.1111/biom.12657. [Epub ahead of print]

PMID:
28112795
6.

Outcome-Dependent Sampling Design and Inference for Cox's Proportional Hazards Model.

Yu J, Liu Y, Cai J, Sandler DP, Zhou H.

J Stat Plan Inference. 2016 Nov;178:24-36. doi: 10.1016/j.jspi.2016.05.001. Epub 2016 May 17.

7.

Exercise and Prognosis on the Basis of Clinicopathologic and Molecular Features in Early-Stage Breast Cancer: The LACE and Pathways Studies.

Jones LW, Kwan ML, Weltzien E, Chandarlapaty S, Sternfeld B, Sweeney C, Bernard PS, Castillo A, Habel LA, Kroenke CH, Langholz BM, Queensberry CP Jr, Dang C, Weigelt B, Kushi LH, Caan BJ.

Cancer Res. 2016 Sep 15;76(18):5415-22. doi: 10.1158/0008-5472.CAN-15-3307. Epub 2016 Aug 3.

PMID:
27488523
8.

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.

9.

Marginal Structural Cox Models with Case-Cohort Sampling.

Lee H, Hudgens MG, Cai J, Cole SR.

Stat Sin. 2016 Apr;26(2):509-526.

10.

Power/sample size calculations for assessing correlates of risk in clinical efficacy trials.

Gilbert PB, Janes HE, Huang Y.

Stat Med. 2016 Sep 20;35(21):3745-59. doi: 10.1002/sim.6952. Epub 2016 Mar 31.

PMID:
27037797
11.

Robust risk prediction with biomarkers under two-phase stratified cohort design.

Payne R, Yang M, Zheng Y, Jensen MK, Cai T.

Biometrics. 2016 Dec;72(4):1037-1045. doi: 10.1111/biom.12515. Epub 2016 Apr 1.

12.

Analysis of two-phase sampling data with semiparametric additive hazards models.

Sun Y, Qian X, Shou Q, Gilbert PB.

Lifetime Data Anal. 2017 Jul;23(3):377-399. doi: 10.1007/s10985-016-9363-2. Epub 2016 Mar 19.

PMID:
26995733
13.

Accelerated failure time model under general biased sampling scheme.

Kim JP, Sit T, Ying Z.

Biostatistics. 2016 Jul;17(3):576-88. doi: 10.1093/biostatistics/kxw008. Epub 2016 Mar 3.

14.

Risk of Pancreatic Cancer in Female Textile Workers in Shanghai, China, Exposed to Metals, Solvents, Chemicals, and Endotoxin: Follow-Up to a Nested Case-Cohort Study.

Reul NK, Li W, Gallagher LG, Ray RM, Romano ME, Gao D, Thomas DB, Vedal S, Checkoway H.

J Occup Environ Med. 2016 Feb;58(2):195-9. doi: 10.1097/JOM.0000000000000596.

15.

Recent progresses in outcome-dependent sampling with failure time data.

Ding J, Lu TS, Cai J, Zhou H.

Lifetime Data Anal. 2017 Jan;23(1):57-82. doi: 10.1007/s10985-015-9355-7. Epub 2016 Jan 13.

PMID:
26759313
16.

Estimating time-varying exposure-outcome associations using case-control data: logistic and case-cohort analyses.

Keogh RH, Mangtani P, Rodrigues L, Nguipdop Djomo P.

BMC Med Res Methodol. 2016 Jan 5;16:2. doi: 10.1186/s12874-015-0104-0.

17.

Kernel machine testing for risk prediction with stratified case cohort studies.

Payne R, Neykov M, Jensen MK, Cai T.

Biometrics. 2016 Jun;72(2):372-81. doi: 10.1111/biom.12452. Epub 2015 Dec 21.

18.

Statistical inference for the additive hazards model under outcome-dependent sampling.

Yu J, Liu Y, Sandler DP, Zhou H.

Can J Stat. 2015 Sep;43(3):436-453.

19.

Augmented case-only designs for randomized clinical trials with failure time endpoints.

Dai JY, Zhang XC, Wang CY, Kooperberg C.

Biometrics. 2016 Mar;72(1):30-8. doi: 10.1111/biom.12392. Epub 2015 Sep 8.

20.

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.

Prentice HA, Tomaras GD, Geraghty DE, Apps R, Fong Y, Ehrenberg PK, Rolland M, Kijak GH, Krebs SJ, Nelson W, DeCamp A, Shen X, Yates NL, Zolla-Pazner S, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Ferrari G, McElrath MJ, Montefiori DC, Bailer RT, Koup RA, O'Connell RJ, Robb ML, Michael NL, Gilbert PB, Kim JH, Thomas R.

Sci Transl Med. 2015 Jul 15;7(296):296ra112. doi: 10.1126/scitranslmed.aab4005.

Supplemental Content

Support Center